2-Keto-D-galactose inhibits DNA synthesis and inhibits the proliferation of in vitro grown Ehrlich ascites tumor cells.This compound is unstable in powder form and other related salt forms are recommended.
dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, which binds to MCL1 with a KD of 30 nM. dmcl-2 activates the apoptosis mechanism by degrading MCL1.This compound is unstable in powder form and other related salt forms are recommended.
MB07803 is an orally available prodrug of an effective, noncompetitive inhibitor of fructose 1,6-bisphosphatase (FBPase) (EC50: 140 nM and t1/2 of 7.6±2.9 h).This compound is unstable in powder form and other related salt forms are recommended.
Eckol inhibits ultraviolet B-induced cell damage by a decrease in oxidative stress in human keratinocytes.This compound is unstable in powder form and other related salt forms are recommended.
KRP-199, a highly potent and selective antagonist for the AMPA receptors, exhibits good neuroprotective effects in vivo.This compound is unstable in powder form and other related salt forms are recommended.
N-5984, a β3-adrenergic receptor agonist, is used potentially for the treatment of obesity, overactive bladder and type 2 diabetes.This compound is unstable in powder form and other related salt forms are recommended.
ProTAME is an inhibitor of APC/CFzr and APC/CCdc20. Combinations of proTAME with topoisomerase inhibitors, doxorubicin and etoposide, significantly increase cell death in primary cells and Multiple Myeloma (MM) cell lines, particularly if TOPIIα levels are first increased through pre-treatment with ProTAME.This compound is unstable in powder form and other related salt forms are recommended.
Ovothiol A protects eggs embryos from the oxidative burst at fertilization and during development.This compound is unstable in powder form and other related salt forms are recommended.
Bisubstrate inhibitor 78 is an inhibitor of nicotinamide N-methyltransferase (NNMT; IC50= 1.41 μM).1It binds the NNMT active site in the binding pockets for the NNMT substrates S-adenosyl-L-methionine (SAM) and nicotinamide . Bisubstrate inhibitor 78 is selective for NNMT over histone-lysine N-methytransferase NSD2 and protein arginine methyltransferase 1 (PRMT1; IC50s = >50 μM for both). It reduces levels of 1-methylnicotinamide in, and inhibits proliferation of, HSC-2 oral cancer cells when used at a concentration of 100 μM.This compound is unstable in powder form and other related salt forms are recommended.